Management of Escalating Aggression in a Polypharmacy-Burdened Adolescent

Medication Management

The American Academy of Child and Adolescent Psychiatry recommends fluoxetine be tapered gradually, not stopped abruptly, to avoid withdrawal symptoms and rebound mood destabilization, with a suggested reduction by 50% (to 10mg daily) for 1-2 weeks, then discontinue 1
The patient's current regimen includes total daily lithium of 750mg, which may be subtherapeutic for aggression control, and consideration should be given to increasing to 900mg daily (300mg TID) with close monitoring 1
Clonidine 0.1mg BID (0.2mg daily) is appropriate for hyperactivity and impulsivity control and should be continued, with monitoring for sedation and hypotension 4
Viloxazine at 200mg daily may be subtherapeutic if ADHD symptoms are contributing to behavioral dysregulation, and can be titrated up to 600mg daily in weekly 200mg increments based on response 3

Close monitoring is essential during this regimen simplification to detect withdrawal symptoms and assess response, with weekly visits for 4 weeks to assess aggression levels, mood stability, and withdrawal symptoms 1
The American Academy of Child and Adolescent Psychiatry recommends implementing structured behavioral plans with clear consequences for aggressive behavior, and considering 1:1 staffing during high-risk periods if in institutional setting 5
Environmental modifications to reduce triggers, such as sensory sensitivities, may be beneficial for patients with a history of neglect and autism 5
Chemical restraint should only be used for severe agitation threatening substantial harm, at lowest effective dose for shortest duration, and only after behavioral interventions fail, as recommended by the American Geriatrics Society and the American Academy of Child and Adolescent Psychiatry 5, 6, 7

Never abruptly discontinue fluoxetine, as this increases risk of withdrawal syndrome and mood destabilization, and never start or adjust lithium without proper laboratory monitoring capabilities, as lithium has a narrow therapeutic index and requires close monitoring 1, 2
Never use benzodiazepines as first-line for agitation in this patient, as they are contraindicated except for specific indications like withdrawal, and do not add more medications before simplifying the current regimen, as polypharmacy itself may be contributing to behavioral dyscontrol 7, 2